Posted: Friday, August 5, 2022
Findings from the phase Ib/II CARTITUDE-1 study, published in Clinical Lymphoma, Myeloma, & Leukemia, suggest that treatment with ciltacabtagene autoleucel may result in substantially improved survival outcomes versus real-world therapies among some patients with relapsed or refractory multiple myeloma. This anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy previously demonstrated efficacy among patients with multiple myeloma who were triple-class–exposed, having received immunomodulatory, proteasome inhibitor, and anti-CD38 monoclonal antibody treatments.
“These findings suggest ciltacabtagene autoleucel may represent a useful treatment option compared with currently available therapies for this patient population with a high unmet need,” concluded Luciano J. Costa, MD, PhD, of the University of Alabama at Birmingham; Shaji Kumar, MD, of the Mayo Clinic, Rochester, Minnesota; and colleagues.
The study used the MAMMOTH data set of patients who were refractory to anti-CD38 monoclonal antibody treatment to identify eligible patients. Enrolled patients in the intent-to-treat population (n = 113) had undergone apheresis; those in the modified intent-to-treat population (n = 97) received ciltacabtagene autoleucel. Corresponding sets of patients were also identified, with 190 in the MAMMOTH intent-to-treat population and 122 in the modified intent-to-treat population. The modified group was defined as having experienced neither disease progression nor death within 47 days of treatment initiation. Overall, 95 and 69 patients from the CARTITUDE-1 intent-to-treat and modified intent-to-treat populations, respectively, were matched with patients from the corresponding MAMMOTH populations.
Patients in both CARTITUDE-1 populations experienced superior overall response rates and progression-free and overall survival versus patients in the MAMMOTH groups. Among the intent-to-treat and modified intent-to-treat populations, overall response rates were 84% versus 28% and 96% versus 30%, respectively.
Disclosure: For full disclosures of the study authors, visit clinical-lymphoma-myeloma-leukemia.com.